Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
| Condition | Glioblastoma |
|---|---|
| Phase | Phase 2 |
| Sponsor | University of Pennsylvania |
| Status | Active, not recruiting |
| Enrollment | 39 participants |
| Interventions | INCMGA00012, INCAGN01876, SRS, Brain surgery |
| Start date | Jun 23, 2020 |
| Completion date | Sep 8, 2022 |
| Results posted | Sep 15, 2023 |
Summary
This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM). The investigators hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses.
Objective Radiographic Response (ORR)
| GITR + PD1, SRS (Cohort A) | 0 % of participants with response |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care — Bryan Allen